Member Info for sadoldgit

You have done the same Glenfiddrich to me in the past. Dont try and be condescending either.

Stop spouting rubbish glenfidrich. Since when have I indicated that we shoulod all have degrees in bio chemistry? A general understanding and reasonable understanding should suffice, along with time consuming research should be sufficient.

Jeez some people!

I think we can expect a little more tick up in the price at the moment.

i believe they use humanised mice in recent studies,

https://www.sciencedirect.com/topics/immunology-and-microbiology/humanized-mouse#:~:text=%20Humanized%20Mouse%20%201%20Humanized%20Mice%20in,transgenic%20mice...%205%20Infectious%20Diseases.%20%20More%20

Smart-inv,
major difference in that SNG were looking at covid 19. Hence big expectation and bigger fall. Covid has taken a back seat at the moment but still poses a threat.

SDC1801 is a TYK2 Jak1 inhibitor aimed at a multitude of targets. Due to its effectiveness at down regulating and correcting problems in our adaptive and innate immune systems, it was was postulated to the reasons for and investigated as an effective treatment for the down regulation of the cytokine storm which can, and does prove fatal in many severe cases of Covid 19. In this instance it would indicate it would most likely be of benefit not only in Covid 19 but also other any other viruses which can cause acute leading to severe respiratory distress syndrome such as MERS.

Covid 19 was a sideline. SDC1801 as opposed to SDC 1802 was selected to treat Covid 19 and as such, it proved to significantly down regulate the cytokine storm and at the same time no increase in viral load was detected. Nothing has changed in this respect to it effectiveness.

In light of the recent Covid 19 nightmare it does remain as yet the most promising and best potential treatment of ARDS. This is a treatment and not to be confused with antivirals. Anti virals have a worthwhile but predominantly short span. With SDC1801 we are fine tuning our immune system to overcome these type of viruses ( by the damage they do) regardless of any mutation.

As already pointed out, our attempts to achieve an MTD at 30 times treatment dose proved futile. Tim did mention that we may have to go as high as 100 times treatment dose to achieve an MTD.
I have no idea how high they went.
What can be said, is that they were encountering problems manufacturing and being able to administer the compounds at such high quantity and dosage levels. A new crystallisation of a compound has been implemented to ensure 100% purity, of the corresponding molecules that make up the compound, as well as a Capsule being utilised for the oral route of intake to ensure maximisation of LADMET properties.

I ramble on a bit as usual, but hope this answers your concern.

Regards

Yes ndr always a degree of uncertainty. Confidence is one thing, confirmation of satisfactory results are something else. Until we receive official confirmation, there exists an element of doubt.

Regards.

Data will be presented in its original form. This will entail the whole caboodle from the formulation of the compounds and how they were made, even down to where the mice were obtained from used in testing. Extremely detailed.
A peer review is one thing and I feel that independent verification will take place before the peer review by an appointed person or persons can be completed.

From memory CHK1, main inhibition is achieved (causing cycle arrest of the P53 checkpoint) by Jak1. Not quite 100% sure on this. Jak2 and especially Jak3 are known to have adverse side effects associated with the dreaded NDA issued Black Box warnings.

Regards

From what I have researched so far from memory. Pure TYK2 can have issues.
We have 2 Tyk 2 Jak 1 molecules, one for immuno and 1 for Oncology. Clearly very finely tuned.
Just because a competitor has a Tyk 2 with potential problems does not mean ours would suffer a similar fate. It does not mean however we are completely all done and dusted. Phase 1 trials will need to be conducted and concluded to determine just how good we are.

Deucravacitinib has proved non successful in IBD and i suspect due to lack of IL-10 inhibition, as pure Tyk 2 which can only inhibit the two IL-10 receptor 2 proteins, however it is Jak1 which inhibits the two IL-10 receptor 1 proteins. Therefore it stands to reason for complete inhibition ie of the two IL-10R1 and the two IL-10 R1 proteins completing four receptors needed for functional IL-10, Jak1 and Tyk2 are required.

Just my input.
Do I think we are better than BMS effort? Yes by far.
Regards

Regards

https://www.globenewswire.com/news-release/2021/07/14/2263094/0/en/Galapagos-reports-positive-topline-results-with-selective-TYK2-inhibitor-GLPG3667-in-Phase-1b-psoriasis-study.html

SW
2nd part of course is release of toxicity results. If we release early prior to consolidation we will have SP rise, some will sell and we will have more volatility as the consolidation and probably raising of funds via share dilution will still be looming. Effectively we remove all the MM negative doubting and lowering of SP after the release after a positive tox result.

In addition releasing just after consolidation will maximise the effect on SP.

In reality there is no difference between consolidation or not. But in marketing as it is funds we require at some stage, it is all down to perception.

regards

I am sure Tim and co are well aware of what PH are up to. PH are not interested in SAR only interested in how much they can glean by careful manipulation and control of the current SP.

My views again.

Regards

Good afternoon Seawolf.
My reasoning is,
for the very same reason investors will come on board when the share is in the pound region plus, so will companies likely to partnership. It looks more attractive. We require due diligence in whom we deal with and so they will do due diligence with us. We operate as a penny share at the moment and that is all we are perceived as I feel.

Shares can be looked at in the same context as a strong currency. The dollar is strong. A high SP creates an impression of strength.
As an example see excerpt regards inflation and deutchmark.

A loaf of bread in Berlin that cost around 160 Marks at the end of 1922 cost 200,000,000,000 Marks by late 1923.

Absolutely no control just mass producing of notes of a higher denomination.

By November 1923, one US dollar was worth 4,210,500,000,000 German marks.

Simalarly but not to be taken as the absolute same is we have circa 3,450,000,000 shares in issue
at the present 4p.
When we reduce 50 to 1 we will have 69,000,000 shares approx at approx 200p per share.

Which looks better? Surely this will ensure SP stability.
Low SP with billions of shares will be looked upon by investors and those with similar opinions as low value currencies with high inflations. A degree of control will look to be seen as a result of consolidation, thus removing the current volatility we have, which investors not like.
In a sense this can be seen as one aspect of marketing.

This is in my opinion of course, we are now far more than a penny share company, hence need to reinforce this by having an SP far greater than it has at the moment. To be seen and perceived by investors, potential partners and potential/future licencees.

Regards and my tuppence worth.

I would hazard a guess that we stand more chance of a 1 billion bid after consolidation. More likely I would think of a partnership of some sort. Either would reinforce the market cap. More than just coincidence that toxicity results follow consolidation I feel. No pressing need to raise funds just yet.

Regards

An astute comment James. All down to how much is required to be raised post consolidation. Consolidation makes no difference on its own. It is all down to raising of funds which i do not think is going to happen until April at the earliest. Fewer shares and price stability to follow.

PH doing their best to suppress.

Regards

Good afternoon SCHeckler

INTERIM RESULTS EXTENSION

Cambridge, UK, 25 March 2021 – Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, advises that it will publish its interim results for the six months ended 30 December 2020, no later than 30 April 2021. The final date will be confirmed in the coming weeks.

As announced by the London Stock Exchange on 9 June 2020 and reconfirmed on 27 January 2021, AIM companies that require extra time to prepare their half-yearly reports are permitted a temporary extension of an additional one-month period, in addition to the standard three-month reporting timeframe under AIM Rule 18 of the AIM Rules for Companies. This extension is due to the continued disruption caused by the COVID-19 pandemic.'

Disruption caused by Covid 19 pandemic? yes most likely delays in reports and progress.

There exists info there that would not have been available ie written into the half year report a month earlier namely completed dose range findings and new formulation to deliver higher dosage levels. Problems being experienced in determining an MTD.

Not much, but bare in mide raising of funds would have been in progress albeit early stages.

Regards

I have been contemplating as to why the TYK2 inhibitor Deucravacitinib.

'Bristol-Myers Squibb’s hopes of extending the use of its highly-anticipated psoriasis pill deucravacitinib into inflammatory bowel disease (IBD) have been hit by a mid-stage failure in ulcerative colitis.'

As far as I can determine IBD inhibition by IL-10 important.

Interleukin-10 (IL-10) is an immunoregulatory cytokine that has been identified as being involved in several diseases including IBD. Studies have shown that polymorphisms in the promoter region reduce serum levels of IL-10 and this reduction has been associated with some forms of IBD.

Note the following 'IL-10 signals through a receptor complex consisting of two IL-10 receptor-1 and two IL-10 receptor-2 proteins'

Interleukin 10 (IL-10), also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine. In humans, interleukin 10 is encoded by the IL10 gene.[5] IL-10 signals through a receptor complex consisting of two IL-10 receptor-1 and two IL-10 receptor-2 proteins.[6] Consequently, the functional receptor consists of four IL-10 receptor molecules. IL-10 binding induces STAT3 signalling via the phosphorylation of the cytoplasmic tails of IL-10 receptor 1 + IL-10 receptor 2 by JAK1 and Tyk2 respectively.

Perhaps now we can fully understand the importance of a small amount ( optimal as described by TIm) of Jak1 as without a Tyk2 inhibitor cannot fully inhibit IL-10.

Regards

Good afternoon Jashar. Not really cashing in as such. Just took an advantage to add on a low and sell one third for a gain. The 150k figure is a post consolidation of 50 to 1 and not 150k as of now.
Enjoy your holiday and trust when you come back you will see the expected gains seen by many who post here. Not all I might add, but some. A market Cap of 500 million plus is not out of the question within 6 months and neither is a 1 billion plus market Cap in the next 12 to 18 months.

Regards

Good post maidit.
We will have a few ups and downs. Synairgen, not surprised, did not meet required end results. Disappointing for some yes. I do feel for them. SDC1801 different league. Proved down regulation of cytokine storm with no increase in viral load. Mind you we are a little more upmarket with much bigger guns than an IL-6 inhaler.

price a little volatile so expect drops in SP with large buys. i added a few at just over 3p and sold one third @ just under 5p, so worked ok for me.

Soon will have close to 150k shares, haha.

Tox results due in 5 weeks and not 8 weeks as posted by one imbecile. Not long to wait.

Who is this Jashar lemon? Not seen so much unsubstantiated drivel posted in a very long time. Nothing informative.

Good posts from yourself maidit, Citizen, Baliff, Celtic, Rebster, Aberystwyth, Ahfam, Thoth and few others i have not mentioned.

Regards to all but one

My opinion for what little tis worth.

Toxicology results will also indicate best targets, for example SLE, lBD, Arthitis.

It will take time and would also hazard a guess that once results accessed and advice from the experts in the field as per RNS then we will get to know for sure, what the targets are and a ball park figure of the amount of funding and dilution required.

Regards.